Real-time Estimate
Cboe BZX
11:08:18 2024-05-07 am EDT
|
5-day change
|
1st Jan Change
|
7.54
USD
|
-0.40%
|
|
+15.38%
|
+27.55%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
350.4
|
341.9
|
808
|
506.4
|
723.8
|
-
|
-
|
Enterprise Value (EV)
1 |
350.4
|
341.9
|
808
|
506.4
|
723.8
|
723.8
|
723.8
|
P/E ratio
|
-0.69
x
|
-4.59
x
|
-4.84
x
|
-2.43
x
|
-3.78
x
|
-3.8
x
|
-5.19
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
44.5
x
|
-
|
-
|
-
|
-
|
546
x
|
8.57
x
|
EV / Revenue
|
44.5
x
|
-
|
-
|
-
|
-
|
546
x
|
8.57
x
|
EV / EBITDA
|
-
|
-
|
-
|
-2.46
x
|
-4.06
x
|
-4.26
x
|
-3.98
x
|
EV / FCF
|
-9.77
x
|
-
|
-
|
-3.24
x
|
-7.95
x
|
-10.2
x
|
-10.1
x
|
FCF Yield
|
-10.2%
|
-
|
-
|
-30.9%
|
-12.6%
|
-9.81%
|
-9.95%
|
Price to Book
|
-
|
-
|
-
|
1.81
x
|
2.68
x
|
2.67
x
|
2.65
x
|
Nbr of stocks (in thousands)
|
31,202
|
39,851
|
69,893
|
86,124
|
95,613
|
-
|
-
|
Reference price
2 |
11.23
|
8.580
|
11.56
|
5.880
|
7.570
|
7.570
|
7.570
|
Announcement Date
|
3/16/21
|
3/15/22
|
3/14/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
7.871
|
-
|
-
|
-
|
-
|
1.325
|
84.49
|
EBITDA
1 |
-
|
-
|
-
|
-205.9
|
-178.4
|
-169.9
|
-181.9
|
EBIT
1 |
-82.2
|
-75.55
|
-147.8
|
-208.1
|
-228
|
-228.6
|
-191.9
|
Operating Margin
|
-1,044.33%
|
-
|
-
|
-
|
-
|
-17,252.86%
|
-227.09%
|
Earnings before Tax (EBT)
1 |
-74.81
|
-72.27
|
-140.2
|
-192.4
|
-215
|
-219.4
|
-184.3
|
Net income
1 |
-179.2
|
-72.27
|
-140.2
|
-192.4
|
-219.7
|
-231.9
|
-187.6
|
Net margin
|
-2,276.81%
|
-
|
-
|
-
|
-
|
-17,498.5%
|
-222.01%
|
EPS
2 |
-16.17
|
-1.870
|
-2.390
|
-2.420
|
-2.001
|
-1.994
|
-1.458
|
Free Cash Flow
1 |
-35.85
|
-
|
-
|
-156.4
|
-91
|
-71
|
-72
|
FCF margin
|
-455.47%
|
-
|
-
|
-
|
-
|
-5,358.01%
|
-85.22%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/21
|
3/15/22
|
3/14/23
|
2/26/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-57.63
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-19.82
|
-25.64
|
-31.42
|
-35.86
|
-36.82
|
-43.74
|
-43.24
|
-47.08
|
-59.58
|
-58.23
|
-55.82
|
-56.92
|
-57.19
|
-58.15
|
-52.5
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-19.08
|
-24.91
|
-30.63
|
-34.93
|
-35.06
|
-39.62
|
-38.59
|
-44.08
|
-55.38
|
-54.36
|
-52.54
|
-53.45
|
-53.96
|
-55.16
|
-48.64
|
Net income
1 |
-19.08
|
-24.91
|
-30.63
|
-34.93
|
-35.06
|
-39.62
|
-38.59
|
-44.08
|
-55.38
|
-54.36
|
-53.41
|
-54.46
|
-55.38
|
-56.56
|
-48.64
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.4800
|
-0.6200
|
-0.6800
|
-0.7100
|
-0.5000
|
-0.5600
|
-0.5400
|
-0.5900
|
-0.6400
|
-0.6300
|
-0.5128
|
-0.4903
|
-0.4974
|
-0.5039
|
-0.3500
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/15/22
|
5/10/22
|
8/9/22
|
11/14/22
|
3/14/23
|
5/9/23
|
8/8/23
|
11/2/23
|
2/26/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-35.9
|
-
|
-
|
-156
|
-91
|
-71
|
-72
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-74.9%
|
-38.8%
|
-27.2%
|
-35.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-62.7%
|
-64.2%
|
-45.3%
|
-41.1%
|
Assets
1 |
-
|
-
|
-
|
307.1
|
342.2
|
511.4
|
456.4
|
Book Value Per Share
2 |
-
|
-
|
-
|
3.240
|
2.830
|
2.840
|
2.850
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
6.86
|
2.8
|
1.4
|
1.4
|
1.4
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
105.65%
|
1.66%
|
Announcement Date
|
3/16/21
|
3/15/22
|
3/14/23
|
2/26/24
|
-
|
-
|
-
|
Last Close Price
7.57
USD Average target price
17
USD Spread / Average Target +124.57% Consensus |
1st Jan change
|
Capi.
|
---|
| +27.55% | 724M | | +9.09% | 106B | | +0.18% | 104B | | +6.81% | 23.25B | | -13.96% | 22.5B | | -6.77% | 18.7B | | -37.08% | 17.95B | | -11.24% | 16.99B | | +7.63% | 14.26B | | +39.17% | 12.76B |
Bio Therapeutic Drugs
|